Because of the heterogeneity of human prostate tumors, Ad-522E-TK may be applied as an adjunct therapy with other AR-targeting modalities for treatment of hormone refractory and bone metastatic prostate cancers. This evidence concerns the gene AR and prostate neoplasm.